Patents by Inventor Fupeng Ma

Fupeng Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11833142
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: December 5, 2023
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Fupeng Ma, Nathaniel F. Ware
  • 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20230037639
    Abstract: The present disclosure provides a compound of Formula (IT or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.
    Type: Application
    Filed: October 4, 2021
    Publication date: February 9, 2023
    Inventors: Rohan Eric John BECKWITH, Simone BONAZZI, Artiom CERNIJENKO, Fupeng MA, Nathaniel F. WARE
  • Naphthyridinone derivatives and their use in the treatment of arrhythmia
    Patent number: 11530213
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: December 20, 2022
    Assignee: Novartis AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Nichola Smith, Ken Yamada, Kayo Yasoshima
  • BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE
    Publication number: 20220387602
    Abstract: Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 14, 2020
    Publication date: December 8, 2022
    Inventors: Luca ARISTA, Valerie BROENNIMANN, Pier Luca D'ALESSANDRO, Lionel DOUMAMPOUOM-METOUL, Marie-Line GOUDE, Christina HEBACH, Gregory John HOLLINGWORTH, Ingrid Karen Jennifer JEULIN, Louise Clare KIRMAN, Julien LORBER, Fupeng MA, Anna VULPETTI, Ken YAMADA, Thomas ZOLLER
  • GLUE DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20220363671
    Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 17, 2022
    Inventors: Jake AXFORD, Rohan Eric John BECKWITH, Simone BONAZZI, Nicole BUSCHMANN, Artiom CERNIJENKO, Janetta DEWHURST, Aleem FAZAL, Matthew James HESSE, Lauren HOLDER, Viktor HORNAK, Hidetomo IMASE, Rama JAIN, Xianming JIN, John Ryan KERRIGAN, Julie LACHAL, Fupeng MA, Hasnain Ahmed MALIK, James R. MANNING, Daniel MCKAY, Robert Joseph MOREAU, Pierre NIMSGERN, Gary O'BRIEN, Anna VULPETTI, Ken YAMADA, Junping ZHAO
  • 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS
    Publication number: 20220340573
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Application
    Filed: June 6, 2022
    Publication date: October 27, 2022
    Inventors: Kelly D. BOSS, Yi FAN, Alec Nathanson FLYER, Declan HARDY, Zhihong HUANG, Kathryn Taylor LINKENS, Jon Christopher LOREN, Fupeng MA, Valentina MOLTENI, Duncan SHAW, Jeffrey SMITH, Catherine Fooks SOLOVAY
  • 1,2,4-oxadiazole derivatives as liver X receptor agonists
    Patent number: 11427586
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: August 30, 2022
    Assignee: NOVARTIS AG
    Inventors: Kelly D. Boss, Yi Fan, Alec Nathanson Flyer, Declan Hardy, Zhihong Huang, Kathryn Taylor Linkens, Jon Christopher Loren, Fupeng Ma, Valentina Molteni, Duncan Shaw, Jeffrey Smith, Catherine Fooks Solovay
  • 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS
    Publication number: 20220064164
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 3, 2022
    Inventors: Kelly D. BOSS, Yi FAN, Alec Nathanson FLYER, Declan HARDY, Zhihong HUANG, Kathryn Taylor LINKENS, Jon Christopher LOREN, Fupeng MA, Valentina MOLTENI, Duncan SHAW, Jeffrey SMITH, Catherine Fooks SOLOVAY
  • 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11185537
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: November 30, 2021
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Fupeng Ma, Nathaniel F. Ware
  • NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
    Publication number: 20210284635
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 15, 2020
    Publication date: September 16, 2021
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Nichola Smith, Ken YAMADA, Kayo YASOSHIMA
  • Naphthyridinone derivatives and their use in the treatment of arrhythmia
    Patent number: 10844055
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: November 24, 2020
    Assignee: NOVARTIS AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima, Nichola Smith
  • 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20200016143
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 16, 2020
    Inventors: Rohan Eric John BECKWITH, Simone BONAZZI, Artiom CERNIJENKO, Fupeng MA, Nathaniel F. WARE
  • NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
    Publication number: 20190263803
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 1, 2019
    Publication date: August 29, 2019
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Ken YAMADA, Kayo YASOSHIMA
  • Naphthyridinone derivatives and their use in the treatment of arrhythmia
    Patent number: 10266531
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 23, 2019
    Assignee: Novartis AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima
  • NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
    Publication number: 20180111932
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 19, 2017
    Publication date: April 26, 2018
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Ken YAMADA, Kayo YASOSHIMA
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8541432
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 24, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8501756
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: August 6, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8492393
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 23, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8486954
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 16, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
    Patent number: RE46558
    Abstract: Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: September 26, 2017
    Assignee: PALOMA PHARMACEUTICALS, INC.
    Inventors: David I. Sherris, Manjinder Gill, Fupeng Ma, Sanjivanjit Kaur Bhal, Robert Dunn-Dufault, Miklos Feher, Peter Redden, Jonathan Schmidt